The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
Summit Continues to Expect 24-week Data Q1 2018, which Could Provide Potential Proof of Mechanism for Ezutromid
An emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, announces the publication of a paper highlighting the anti-biofilm activity of CERAMENT®
Former chairman of Sanofi to help drive the commercialization of Pertinax®
Study to evaluate safety and efficacy as monotherapy and in combination with anti-PD-1 checkpoint blockade
AMSBIO has introduced a new range of Herpes Virus Entry Mediator (HVEM) products for use in immuno-oncology research.
OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, today announced that Glyn Edwards is to join the board as Non-Executive Director.
New Preclinical Data Show Utrophin's Positive Effect on Mitochondria Improving Muscle Health in DMD Model
Macrophage Pharma Presents Data on Lead Immuno-Oncology Programme at SITC Conference - validating ESM™ technology platform
Entering revenue share in accordance with terms of prior Wellcome Trust funding award agreement
The Fight For Our Lives exhibition, which opens at the Science Museum in London on November 9th.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.